Articles | Volume 8, issue 3
https://doi.org/10.5194/jbji-8-175-2023
https://doi.org/10.5194/jbji-8-175-2023
Original full-length article
 | 
28 Jun 2023
Original full-length article |  | 28 Jun 2023

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus

Aaron K. Hoyt, Patrick Lawler, Mathias Bostrom, Alberto V. Carli, and Ashley E. Levack

Viewed

Total article views: 461 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
326 109 26 461 27 25
  • HTML: 326
  • PDF: 109
  • XML: 26
  • Total: 461
  • BibTeX: 27
  • EndNote: 25
Views and downloads (calculated since 28 Jun 2023)
Cumulative views and downloads (calculated since 28 Jun 2023)

Viewed (geographical distribution)

Total article views: 425 (including HTML, PDF, and XML) Thereof 425 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 
Latest update: 10 May 2024
Download
Short summary
This study investigates the ability of a promising new antibiotic, dalbavancin, to be used as an antibiotic incorporated into polymethyl methacrylate (PMMA) cement or other carriers (such as calcium sulfate) to treat bone and joint infections. For antibiotics to be used locally, they must retain their efficacy after heat exposure during PMMA polymerization and at human core body temperature. This study demonstrates that dalbavancin is stable at the temperatures required for local use.